FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Marketing

Attorney Warns: FDA Watching Professional Promotion

Attorney Nathan Downing says medical product companies should review their professional promotions as strictly as they review direct-to-consumer mater...

latest-news-card-1
Human Drugs

Patritumab BLA Pulled by Merck/Daiichi

Merck and Daiichi Sankyo say they have withdrawn their BLA for the lung cancer drug patritumab deruxtecan.

latest-news-card-1
Biologics

Congressmen Hit FDA Covid Vaccine Limit

Eight congressional Democrats call on FDA to eliminate its new limits on Covid-19 vaccines.

latest-news-card-1
Human Drugs

Drug Product Color Additive Replacement Guide

FDA publishes a draft guidance with recommendations for replacing color additives in approved or marketed drug products.

latest-news-card-1
Human Drugs

Experimental Pancreatic Cancer Drug Gets Fast Track

FDA grants the Experimental Drug Development Center a fast-track designation for EBC-129 and its use for treating pancreatic ductal adenocarcinoma.

latest-news-card-1
Human Drugs

Beam Gets Orphan Status for Genetic Disorder

FDA grants Beam Therapeutics an orphan drug designation for BEAM-302, a liver-targeting lipid-nanoparticle that is designed to correct the disease-cau...

Medical Devices

Multiple Issues at Germanys DRG Instruments

FDA warns Marburg, Germany-based DRG Instruments that it is marketing diagnostic devices that do not have FDA approval and are being manufactured with...

FDA General

House Democrats Want Answers on HHS Staff Cuts

Complaining about a lack of information from the department, top Democrats on the House Energy and Commerce Committee ask HHS Secretary Robert F. Kenn...

Medical Devices

FDA Publishes 2 Q-Submission Guidances

FDA publishes two guidances relating to the CDRH/CBER Q-submission process.

Animal Drugs

GSK Plans for Antibiotic NDA in 2nd Half

GSK plans to submit an NDA in the second half of the year after it and Spero Therapeutics announced that they will end their Phase 3 PIVOT-PO clinical...